 "Rivals Cipla, Natco gain on Novartis drug patent rejection")
Mumbai: Shares in Natco Pharma and Cipla gain after the Supreme Court dismissed Swiss drugmaker Novartis AG’s petition seeking patent for its cancer drug Glivec.
[caption id=“attachment_680976” align=“alignleft” width=“380”] Analysts say that will be a big win for generic drugmakers. Reuters[/caption]
In a landmark judgment that has the potential to change the direction of India’s pharmaceutical business, the Supreme Court said on Monday that the drug failed to qualify for a patent according to Indian law.
Analysts say that will be a big win for generic drugmakers given huge difference in prices of monopoly drugs, and as other emerging countries are also expected to follow he apex court’s decision.
Cipla and Natco are already selling generic versions of Glivec in India. Natco was up 6 percent, while Cipla rose 2 percent at 2:25 pm
Reuters
 "Russian drones over Poland: Trump’s tepid reaction a wake-up call for Nato?")
 "As Russia pushes east, Ukraine faces mounting pressure to defend its heartland")
 "Why Mossad was not on board with Israel’s strike on Hamas in Qatar")
 "Turkey: Erdogan's police arrest opposition mayor Hasan Mutlu, dozens officials in corruption probe")
 "Russian drones over Poland: Trump’s tepid reaction a wake-up call for Nato?")
 "As Russia pushes east, Ukraine faces mounting pressure to defend its heartland")
 "Why Mossad was not on board with Israel’s strike on Hamas in Qatar")
 "Turkey: Erdogan's police arrest opposition mayor Hasan Mutlu, dozens officials in corruption probe")
